

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Dinutuximab for treating high-risk neuroblastoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was noted during consultation that, because dinutuximab-based therapy is very costly, if it is shown to be clinically and cost effective, failure to achieve NICE approval would result in inequitable access to this therapy for children within UK.

At the scoping workshop, a stakeholder indicated that, because dinutuximab therapy is not available in clinical trials in Europe, some patients travel to the US to receive it.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Neither of these issues is considered to be a potential equality issue that needs addressing by the Committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No change to the draft scope has been agreed.

4. Have any additional stakeholders related to potential equality issues

been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues have been identified.

Approved by Associate Director (name): Helen Knight

Date: 08/05/2015